roflumilast

Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

Roflumilast Impurity E is an impurity of Roflumilast, which acts as a selective and long-acting enzyme PDE-4 inhibitor (IC50 value of 0.8 nM).

Roflumilast N-oxide is an inhibitor of PDE type 4.

Roflumilast N-Oxide-d4 is a deuterated compound of Roflumilast N-Oxide. Roflumilast N-Oxide has a CAS number of 292135-78-5. Roflumilast N-oxide is a PDE type 4 inhibitor.

D-159404, as an allosteric inhibitor, demonstrates superior inhibitory effects on the full-length PDE 4D3 compared to its truncated form and exhibits higher cellular activity. This sets it apart from competitive inhibitors like roflumilast and cilomilast. These findings indicate that D-159404 and related compounds may offer valuable insights into PDE 4 pharmacology and serve as strong candidates for further study on cAMP signaling's impact on disease treatment.